Fact-checked by Grok 2 weeks ago

Selinexor

Selinexor, marketed under the brand name Xpovio, is an oral first-in-class selective inhibitor of nuclear export (SINE) approved for the treatment of adults with relapsed or (MM) and (DLBCL). Developed by Karyopharm Therapeutics, it targets exportin-1 (XPO1), a key protein responsible for shuttling tumor suppressor proteins, growth regulators, and oncoproteins out of the , thereby forcing their accumulation in the to induce cancer cell and inhibit . The U.S. (FDA) first granted accelerated approval to selinexor in July 2019 in combination with dexamethasone for adult patients with relapsed or MM who have received at least four prior therapies and whose disease is to at least two inhibitors, at least two immunomodulatory agents, and an anti-CD38 . This approval was based on the IIb STORM trial, which demonstrated an overall response rate of 25.3% in heavily pretreated patients. In December 2020, the FDA converted this to regular approval and expanded the indication to include patients with MM after at least one prior line of therapy, supported by the III BOSTON trial showing improved when combined with and dexamethasone compared to standard therapy. Additionally, in June 2020, selinexor received accelerated approval as a monotherapy for adults with relapsed or DLBCL after at least two prior systemic therapies, based on the IIb SADAL trial with an overall response rate of 28%. Selinexor's mechanism of action represents a novel therapeutic approach in oncology by disrupting nuclear-cytoplasmic transport, a process often dysregulated in cancers, leading to the reactivation of tumor suppressor functions and downregulation of oncogenic pathways without directly targeting DNA. It is administered orally, with recommended dosing of 80 mg on Days 1 and 3 weekly with dexamethasone for heavily pretreated MM, 100 mg once weekly with bortezomib and dexamethasone for MM after one prior therapy, or 60 mg on Days 1 and 3 weekly as monotherapy for DLBCL, alongside supportive care for common adverse effects such as nausea, fatigue, and thrombocytopenia. It has also received approvals in various countries, including China in July 2025 for MM combination therapy. As of 2025, ongoing clinical trials are investigating its potential in other malignancies, including endometrial cancer (SIENDO trial) and myelofibrosis (SENTRY trial, enrollment completed September 2025).

Clinical Aspects

Medical Uses

Selinexor is approved by the US Food and Drug Administration (FDA) and the () for the treatment of relapsed or refractory (RRMM) in adults. The FDA indication includes use in combination with dexamethasone for patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 . It is also approved in combination with and dexamethasone for adults who have received at least one prior line of therapy. The EMA authorizes selinexor in combination with dexamethasone for adults with RRMM who have received at least four prior therapies meeting similar refractoriness criteria, and in combination with and dexamethasone for those with at least one prior therapy. As the first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor addresses an unmet need in quadruple- or penta-refractory patients, where standard therapies have failed. In the pivotal phase 2b trial evaluating selinexor plus dexamethasone in penta-refractory RRMM patients, the overall response rate (ORR) was 25.3%, with a duration of response of 3.8 months among responders. This regimen provides a that promotes nuclear retention of tumor suppressor proteins, offering clinical benefit in heavily pretreated cases despite common adverse effects such as that may require monitoring in eligible patients. Selinexor is also approved by the FDA as monotherapy for the treatment of adult patients with relapsed or refractory (DLBCL), not otherwise specified—including DLBCL arising from —after at least two prior lines of . Patient eligibility typically requires ineligibility for or failure of and prior therapies including anti-CD20 monoclonal antibodies, but excludes those with high-grade lymphomas other than DLBCL. In the phase 2b SADAL trial of monotherapy selinexor in relapsed or refractory DLBCL after two to five prior therapies, the ORR was 28.3%, including a 12.1% complete response rate, with responses observed across B-cell and non- B-cell subtypes.

Adverse Effects

Selinexor treatment is commonly associated with hematologic and gastrointestinal adverse effects. The most frequent adverse events reported in clinical trials include (73% all grades, 58% Grade 3/4), (72% all grades, 9% Grade 3/4), (73% all grades, 25% Grade 3/4), (52% all grades, 44% Grade 3/4), and (40% all grades, 24% Grade 3/4). These effects are observed across indications such as and (DLBCL), where selinexor is frequently used in relapsed or refractory settings. Serious adverse risks encompass gastrointestinal toxicity, including and , neurological effects such as and , and secondary to (20% 3/4). The FDA prescribing information highlights boxed warnings for fatal , , and , emphasizing the need for vigilant monitoring to mitigate these potentially life-threatening complications. Adverse effects are managed through dose interruptions or reductions—for instance, reducing from 80 mg to 60 mg weekly—as well as supportive measures like antiemetics for and thrombopoietin mimetics for . In pivotal trials, approximately 19% of patients discontinued selinexor due to adverse events, underscoring the importance of proactive tolerability strategies.

Dosage and Administration

Selinexor is administered orally in tablet form for the treatment of relapsed or refractory (RRMM) and (DLBCL). For RRMM in combination with dexamethasone (Xd regimen), the recommended dosage is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity. In combination with and dexamethasone (XVd regimen) for RRMM after at least one prior line of therapy, the dosage is 100 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity. For adult patients with relapsed or refractory DLBCL after at least two prior systemic therapies, the recommended dosage is 60 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity. Tablets should be swallowed whole with water, with or without food, at approximately the same time each day; they must not be broken, chewed, crushed, or divided. If a dose is missed or vomited, the next dose should be taken at the regularly scheduled time without doubling the dose. Prophylactic antiemetics, such as a 5-HT3 receptor antagonist and an , are recommended prior to each dose to manage and . Patients should maintain adequate fluid and caloric intake throughout treatment. Monitoring of complete blood counts (), blood chemistries including electrolytes, and weight is required at baseline and regularly during treatment, with increased frequency during the first three months to detect hematologic toxicities early. Dose interruptions and reductions are recommended for adverse reactions, with stepwise reductions available: for the 80 mg or 60 mg twice-weekly regimens, reduce to 60 mg or 40 mg, respectively, on Days 1 and 3; for the 100 mg once-weekly regimen, reduce to 80 mg, then 60 mg weekly.
Adverse ReactionDosage Modification Guidelines
Hematologic Toxicities (e.g., , , )Grade 3/4: Interrupt until recovery to Grade 2 or less, then resume at reduced dose.
Platelets <25,000/mcL: Interrupt and transfuse if needed; resume at reduced dose.
Non-Hematologic Toxicities (e.g., Nausea ≥Grade 3, Diarrhea ≥Grade 3, Hyponatremia)Grade 3/4: Interrupt until recovery to Grade 2 or less, then resume at reduced dose with supportive care.
For persistent Grade 2 non-hematologic toxicity: Consider dose reduction.
No dose adjustment is required for patients with mild hepatic impairment (total bilirubin > upper limit of normal to ≤1.5 times ULN and any ). The pharmacokinetics of selinexor are not significantly altered in patients with mild to severe renal impairment ( clearance 15–89 mL/min), so no dosage adjustment is necessary. However, data are limited for end-stage renal disease ( clearance <15 mL/min) or patients on dialysis, and the effect on is unknown.

Pharmacology

Mechanism of Action

Selinexor is a selective inhibitor of nuclear export (SINE) that covalently binds to cysteine 528 (Cys528) in the cargo-binding pocket of (XPO1, also known as CRM1), forming a slowly reversible bond that blocks its nuclear export function. This selective binding prevents XPO1 from recognizing and exporting nuclear export signal (NES)-bearing cargo proteins, leading to their forced retention in the nucleus. Unlike non-selective inhibitors, selinexor exhibits high specificity for XPO1 at therapeutic concentrations, with minimal off-target effects on other nuclear transport proteins. The inhibition of XPO1 by selinexor results in the nuclear accumulation of key tumor suppressor proteins, including , , , (the endogenous inhibitor of ), and . This retention reactivates suppressed tumor suppressor pathways, as these proteins are unable to shuttle to the cytoplasm where they would be inactivated or degraded. Consequently, selinexor reduces the nuclear export and cytoplasmic stabilization of oncoproteins such as and , disrupting proliferative signaling. These molecular changes induce G1/S phase cell cycle arrest, impair DNA damage repair mechanisms, and promote apoptosis through pathways like activation and suppression, with effects being more pronounced in cancer cells due to their dysregulated transport dependencies. XPO1 is overexpressed in many human cancers across solid and hematologic malignancies, where elevated levels correlate with aggressive disease and poor patient prognosis by facilitating the mislocalization of tumor suppressors. Selinexor exploits this overexpression to selectively reactivate oncogenic pathways in malignant cells while sparing normal nuclear transport at clinically relevant doses, as non-cancerous cells maintain lower XPO1 activity and can tolerate transient disruptions without undergoing apoptosis.

Pharmacokinetics

Selinexor is rapidly absorbed after oral . The time to maximum concentration (Tmax) is approximately 4 hours, and with the recommended twice-weekly dosing regimen, steady-state concentrations are reached without clinically relevant accumulation. Concomitant with does not significantly alter the . The drug is highly bound to proteins, with 95% binding. Selinexor has an apparent of 125 L, suggesting extensive tissue penetration, including into the . This distribution profile supports its nuclear accumulation in target cells, consistent with its . Metabolism of selinexor involves multiple pathways, including CYP3A4, UDP-glucuronosyltransferases (UGTs), and glutathione S-transferases (GSTs); no active metabolites are formed. The elimination half-life is 6-8 hours, and the apparent clearance is 19 L/h. Excretion is primarily fecal via the hepatobiliary route, with minimal elimination in the urine (<1% as unchanged drug). Clearance is not significantly affected by age, sex, mild renal impairment, or mild hepatic impairment. Due to its metabolism involving CYP3A4, potential interactions with strong CYP3A4 inducers or inhibitors should be monitored in clinical use, though selinexor does not significantly inhibit or induce major CYP enzymes or transporters.

Chemical Properties

Selinexor is a small molecule with the chemical formula C_{17}H_{11}F_6N_7O and a molecular weight of 443.31 g/mol. Its IUPAC name is (2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide, and it has the CAS number 1393477-72-9. The molecular structure consists of a central 1,2,4-triazole ring substituted at the 3-position with a 3,5-bis(trifluoromethyl)phenyl group and at the 1-position with a (Z)-3-(N'-pyrazin-2-ylprop-2-enehydrazide) chain, featuring an α,β-unsaturated hydrazide moiety that contributes to its reactivity. Physically, selinexor appears as a white to off-white, non-hygroscopic powder and is classified as a (BCS) class 2 drug due to its low aqueous and high permeability. It is practically insoluble in ( approximately 0.00555 mg/mL) but soluble in solvents such as and DMSO. The compound is lipophilic, with a calculated value of approximately 3.5, and has a of 10.20 for its ionizable group, influencing its and properties. In , selinexor exhibits high stability, remaining >90% intact over 24 hours, and is approximately 95% bound to proteins. Selinexor binds covalently yet reversibly to exportin-1 (XPO1) through a involving its acrylate-like moiety and the 528 residue in XPO1's cargo-binding groove, with a dissociation of about 24 hours. This targeted interaction disrupts XPO1's function without permanent inactivation. Selinexor was developed as part of the KPT (Karyopharm Therapeutics) series of selective inhibitors of nuclear export (SINE) compounds, designed to selectively engage the XPO1 cargo-binding groove while minimizing off-target effects compared to earlier inhibitors like leptomycin B.

Development

Discovery and Preclinical Studies

Selinexor, also known as KPT-330, was discovered by Karyopharm Therapeutics Inc., a company founded in 2008 to develop selective inhibitors of nuclear export (SINE) compounds targeting XPO1 (exportin-1, also called CRM1). The compound emerged from efforts focused on identifying small molecules that inhibit XPO1 function by binding covalently to its cysteine 528 residue in the () binding groove, a approach informed by including . This screening process prioritized analogs with potent, selective, and slowly reversible inhibition of XPO1-mediated nuclear export, distinguishing selinexor from earlier, more toxic XPO1 inhibitors like leptomycin B. Initial identification and optimization occurred around 2009–2010, leading to selinexor's selection as the lead clinical candidate by 2012, when it entered Phase 1 trials. Preclinical studies demonstrated selinexor's potency , with an of approximately 20 nM for XPO1 inhibition in U2OS cells and a median of 165 nM across (MM) cell lines, reflecting effective blockade of nuclear export. It induced dose-dependent in cancer cell lines from MM, (AML), and by promoting nuclear retention of tumor suppressor proteins (e.g., , IκB) and reducing cytoplasmic levels of oncoproteins (e.g., c-Myc, ), while exhibiting minimal to normal hematopoietic cells at therapeutic concentrations. In models overexpressing XPO1, selinexor reversed aberrant nuclear export, restoring tumor-suppressive functions and highlighting its utility in XPO1-dysregulated malignancies. In vivo efficacy was confirmed in xenograft models using immunodeficient mice implanted with human MM (e.g., MM.1S, H929), AML, and cells, where oral selinexor administration (typically 10–15 mg/kg twice weekly) significantly reduced tumor growth or induced regressions without substantial body weight loss or overt toxicity to normal tissues. Oral was high in preclinical species, reaching 61% in rats and 68% in monkeys, supporting twice-weekly dosing regimens. Good laboratory practice (GLP) studies in rats and dogs revealed no in standard assays (, chromosomal aberration, micronucleus) and no significant , with an hERG channel of 20.6 μM indicating low risk for prolongation. The promising preclinical profile led to regulatory recognition, including FDA designation for on January 5, 2015, which provided incentives for further development in this .

Clinical Trials Leading to Approval

The pivotal clinical trials that led to the regulatory approvals of selinexor were primarily focused on its use in relapsed or refractory (RRMM) and (DLBCL). The STORM trial, a phase IIb, single-arm, open-label, multicenter study, evaluated selinexor in combination with low-dose dexamethasone in 122 patients with heavily pretreated RRMM who had received at least four prior therapies and were refractory to , , , and (penta-refractory). Patients received selinexor 80 mg twice weekly orally. The overall response rate (ORR), the primary endpoint, was 25.3% (95% CI, 18.0-34.1), including 2% complete responses, with a (PFS) of 3.7 months. These results supported the U.S. Food and Drug Administration's (FDA) accelerated approval of selinexor with dexamethasone on July 3, 2019, for adult patients with RRMM after at least four prior therapies. The SADAL trial, a phase II, single-arm, open-label, multicenter , assessed selinexor monotherapy in 127 patients with relapsed or DLBCL after two to five prior systemic therapies. Participants received selinexor 60 mg orally twice weekly. The ORR, the primary endpoint, was 28.3% (95% CI, 20.7-37.2), with 12% achieving complete responses and a duration of response of 9.2 months. This trial provided the basis for the FDA's accelerated approval of selinexor monotherapy on June 22, 2020, for adult patients with relapsed or DLBCL (not otherwise specified), primary mediastinal large , or grade 3b after at least two prior systemic therapies. Subsequently, the BOSTON trial, a phase III, randomized, open-label, active-comparator , compared selinexor in combination with and dexamethasone (SVd) versus and dexamethasone (Vd) in 402 patients with RRMM who had received one to three prior lines of . Patients in the SVd arm received selinexor 70 mg once weekly, 1.3 mg/m² subcutaneously once weekly for the first two cycles then biweekly, and dexamethasone 20 mg twice weekly; the Vd arm used the same and dexamethasone schedule without selinexor. The primary endpoint of PFS was significantly improved with SVd at a median of 13.93 months versus 9.66 months with Vd ( 0.70; 95% CI, 0.54-0.89; P=0.004), and the ORR was 83.3% versus 65.6%. These findings led to the FDA's approval of selinexor with and dexamethasone on December 18, 2020, for adult patients with RRMM after at least one prior line of . Across these trials, safety data highlighted the tolerability profile of selinexor, with higher rates of discontinuation due to adverse in the trial (18.6%) compared to (25.7% in SVd arm versus 18.6% in Vd arm), primarily driven by hematologic toxicities and gastrointestinal effects, though dose modifications mitigated many issues.

Regulatory Approvals

Selinexor received accelerated approval from the U.S. (FDA) on July 3, 2019, for use in combination with dexamethasone in adult patients with relapsed or (RRMM) who have received at least four prior therapies and whose disease is to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 . This approval was based on the trial and required confirmatory studies to verify clinical benefit. On December 18, 2020, the FDA granted regular approval to selinexor in combination with and dexamethasone for the treatment of adult patients with RRMM following at least one prior therapy. The agency also granted accelerated approval on June 22, 2020, for selinexor monotherapy in adult patients with relapsed or (DLBCL), not otherwise specified, after at least two prior systemic therapies. This indication similarly requires confirmatory trials as a post-approval commitment. As of November 2025, the DLBCL indication remains under accelerated approval, with confirmatory trials such as XPORT-DLBCL-030 ongoing to verify clinical benefit. The (EMA) recommended conditional marketing authorization for selinexor (as Nexpovio) on January 28, 2021, which was granted by the on March 26, 2021, for use in combination with dexamethasone for adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two inhibitors, two immunomodulatory agents, and an anti-CD38 , as well as for monotherapy in adult patients with relapsed or refractory DLBCL after at least two prior therapies. On July 18, 2022, the EMA converted the conditional marketing authorization to full marketing authorization, including the expanded indication of selinexor in combination with and dexamethasone for adult patients with RRMM after at least one prior therapy, as well as the original indications for penta-refractory MM and DLBCL. Selinexor has also received regulatory approvals in other regions. The Therapeutic Goods Administration (TGA) in Australia approved selinexor (as Xpovio) on March 3, 2022, in combination with bortezomib and dexamethasone for adult patients with RRMM after at least one prior therapy. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved selinexor on March 26, 2021, for the treatment of RRMM in patients who have received at least four prior therapies. Health Canada authorized selinexor (as Xpovio) on May 31, 2022, in combination with bortezomib and dexamethasone for adult patients with RRMM following at least one prior therapy. China's National Medical Products Administration (NMPA) approved selinexor monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies on July 8, 2024, and in combination with bortezomib and dexamethasone for adult patients with RRMM after at least one prior therapy on July 28, 2025. Post-approval requirements for selinexor's accelerated approvals include ongoing confirmatory clinical trials to verify and describe the anticipated clinical benefit, particularly for the DLBCL indication and the original RRMM regimen. Management of risks such as and is addressed through product labeling, including recommendations for monitoring and dose adjustments, without a dedicated Risk Evaluation and Mitigation Strategy (REMS) program.

Society and Culture

Brand Names and Availability

Selinexor is marketed under the brand name Xpovio in the United States by Karyopharm Therapeutics Inc. In the , it is available as Nexpovio under an exclusive license to the Group. Karyopharm Therapeutics Inc., headquartered in , manufactures selinexor, which is supplied as film-coated tablets in 10 mg, 20 mg, 40 mg, 50 mg, and 60 mg strengths. Xpovio launched in the United States in 2019 after FDA approval, and Nexpovio became available in the in 2021 following conditional marketing authorization. The drug is distributed exclusively through specialty pharmacies in approved markets to ensure proper handling and patient support. In the United States, the wholesale acquisition cost for a typical monthly dose of Xpovio was approximately $22,000 as of 2019, with similar pricing reported around $23,000 in 2023 data. The U.S. composition-of-matter for selinexor (No. 8,999,996) expires in 2033 following a term extension, while additional patents covering the commercial polymorph extend protection to 2035; no generic versions are currently available. In the United States, selinexor is classified as a prescription-only medication approved by the (FDA) for specific indications, but it is not designated as a under the (DEA) schedules. In the , selinexor holds centralized marketing authorization from the (EMA), initially granted as conditional approval in 2021 for relapsed or refractory , which was converted to full marketing authorization in 2022 following confirmatory data submission; this status includes ongoing obligations for post-marketing studies to verify long-term benefits and risks. It is not classified as a . Selinexor has received orphan drug designation in the United States for and (DLBCL), providing incentives such as market exclusivity and tax credits to support development for these rare conditions. In the European Union, it has orphan designation for . As of mid-2025, selinexor is approved in over 50 countries worldwide through partnerships with Karyopharm Therapeutics, though access remains limited in low-resource settings primarily due to its high cost. To support access, Karyopharm's KaryForward Patient Assistance Program provides selinexor at no cost to eligible uninsured or underinsured patients who meet income and residency criteria. No generic versions of selinexor are anticipated before expiration in the early , delaying potential competition.

Ongoing Research

Multiple Myeloma

Post-approval studies have confirmed the sustained progression-free survival (PFS) benefits of selinexor in combination with bortezomib and dexamethasone (SVd) for patients with relapsed or refractory multiple myeloma (RRMM), as demonstrated in the 2023 update of the BOSTON trial. In this analysis, longer follow-up showed a median PFS of 13.93 months with SVd compared to 9.66 months with bortezomib and dexamethasone alone, highlighting the regimen's enduring efficacy in triple-class exposed patients. Furthermore, dose reductions to 60 mg weekly in the BOSTON study were associated with improved outcomes, including a median PFS of 16.6 months (versus 9.2 months without reduction) and an overall response rate (ORR) of 81.7% (versus 66.7%), alongside reduced treatment-emergent adverse event rates such as nausea (7.3% versus 31.6% duration-adjusted). The phase II STOMP trial (2022-2024 updates) evaluated selinexor in combination with and dexamethasone (SPd) in patients with RRMM, reporting an overall ORR of 39.5% (55% with the 60 mg weekly dose [n=20] and 31.3% with the 40 mg weekly dose [n=16]), with rates of very good partial response or better at 19.8% overall. These results indicate preliminary efficacy in heavily pretreated patients, including those to and . Safety data from the trial as of March 2024 showed manageable gastrointestinal effects, with occurring in 61.7% of patients overall (any grade) but grade 3-4 events in only 1.2%, supporting the tolerability of the all-oral SPd regimen. In 2025 updates, weekly low-dose selinexor (40-60 mg) combined with other agents has demonstrated a reduced profile, with lower incidence of grade ≥3 non-hematological toxicities like and compared to higher or twice-weekly dosing, while maintaining comparable efficacy such as ORRs of 50-65% in RRMM cohorts from trials like STOMP and . This optimization approach enhances tolerability without compromising response rates or PFS in triple-class settings. Karyopharm's ongoing II trial, including evaluations of selinexor plus , , and dexamethasone in newly diagnosed (NCT04782687), suggests potential for frontline maintenance strategies, though confirmatory data remain pending. Real-world evidence from 2024 registry analyses in penta-exposed and penta-refractory patients treated with selinexor-containing regimens reported a median overall survival of 15.9 months in penta-exposed cohorts, corresponding to an estimated 12-month OS rate of approximately 70% in this high-risk population. These findings underscore selinexor's role in extending survival beyond standard therapies in real-world settings for patients with limited options post-multiple lines of treatment.

Other Hematologic Malignancies

Following its approval for relapsed or (DLBCL) after at least two prior therapies, selinexor has been evaluated in post-approval expansions for this indication, particularly in combination regimens and high-risk subgroups such as CAR-T cases. In a phase II trial (NCT02227251), selinexor monotherapy demonstrated an overall response rate (ORR) of 28.3% in heavily pretreated patients with DLBCL, with durable responses observed in a subset. Further investigations have explored selinexor with rituximab in relapsed settings; preliminary data from a phase Ib/II study combining selinexor, rituximab, and platinum-based in , including DLBCL, reported promising activity with manageable , though specific ORR for the DLBCL cohort was not detailed in initial reports. In 2024 updates from a phase II study focusing on TP53-altered DLBCL (often CAR-T ), selinexor showed encouraging responses, highlighting its potential in this challenging population where exportin 1 overexpression contributes to resistance. In myelofibrosis, phase II studies have assessed selinexor in combination with ruxolitinib for patients with suboptimal responses. The SENTRY trial (XPORT-MF-034; NCT04562389; phase 1b/3, ongoing) evaluated selinexor plus ruxolitinib, reporting spleen volume reduction of ≥35% in 33% of efficacy-evaluable patients (n=12), alongside hemoglobin stabilization in a majority; enrollment in the phase 3 portion was completed in September 2025. Karyopharm's May 2025 announcement emphasized meaningful symptom improvements with this regimen, suggesting disease-modifying potential through XPO1 inhibition in JAK inhibitor-experienced cases. These findings build on earlier phase II data from similar cohorts, where the combination achieved spleen responses in over 40% of participants with tolerable safety. For (AML), a 2023 phase II study of selinexor in relapsed/ cases reported an ORR of 25%, primarily in patients unfit for intensive . Ongoing combinations with , such as in the phase Ib/II SELCLAX trial (NCT03955783), have shown preliminary tolerability and activity in R/R AML, with efforts to optimize sequencing for venetoclax-exposed patients. These investigations target XPO1-mediated nuclear export dysregulation common in AML blasts. Across these malignancies, 2025 data support lower weekly dosing (e.g., 40-60 mg) to enhance tolerability in frail patients, reducing grade 3/4 adverse events like while preserving efficacy, as seen in myelofibrosis and extended to DLBCL/AML cohorts.

Solid Tumors and Other Applications

Selinexor has been investigated in several solid tumor types, though clinical efficacy has generally been modest, with no regulatory approvals achieved to date. In advanced dedifferentiated , the SEAL trial, a phase 2/3 randomized, double-blind, -controlled study conducted from 2016 to 2021 with results reported in 2022, evaluated selinexor monotherapy at 80 mg weekly versus in patients previously treated with and at least two additional systemic therapies. The overall response rate (ORR) was low at 2.7% for selinexor compared to 0% for , while 46.8% of selinexor-treated patients achieved (PFS) of at least 12 weeks versus 34.0% on , indicating a control rate approximating 50% through stable ; median PFS was modestly improved at 2.8 months versus 2.1 months ( 0.70, P=0.011), but the limited ORR and overall response underscored constrained antitumor activity. In (), a phase II trial of selinexor monotherapy in metastatic disease, reported in 2019, enrolled 21 patients previously treated with taxanes and , administering 60 mg orally twice weekly. No objective responses were observed (ORR 0%), though the clinical benefit rate, including stable disease, reached 30%, with median PFS of 2.3 months; was manageable but included 3/4 in 19%. Ongoing investigational combinations, such as selinexor with eribulin in a phase Ib study of advanced solid tumors including (reported 2022), showed an ORR of 10% overall and disease control exceeding 6 months in 15% of patients, suggesting potential for enhanced activity in combination regimens, though no pembrolizumab-specific data in cohorts were confirmed in recent reports. For prostate cancer, a phase II trial of selinexor in metastatic castration-resistant disease refractory to abiraterone and/or , published in 2018, treated 16 patients with 60 mg twice weekly. Any (PSA) decline occurred in 50% of patients, with 14% achieving a ≥50% decline, and median PFS was 2.8 months; development in this indication remains limited due to modest outcomes. Preclinically, selinexor exhibits excellent brain penetration, supporting exploration in models where it reduces proliferation and synergizes with or radiation, though clinical translation has been slow with no recent approvals anticipated. Beyond oncology, selinexor was evaluated as a potential antiviral in a phase II randomized trial for severe (NCT04349098), initiated in 2020 with low-dose 20 mg three times weekly versus in hospitalized patients. The trial, completed in 2021, showed higher 28-day mortality in the selinexor arm (15.2% versus 3.9%), prompting discontinuation of antiviral development pursuits. Overall, selinexor's application in solid tumors reflects nuclear export inhibition's conceptual promise in XPO1-overexpressing malignancies, but modest response rates and toxicity profiles indicate no near-term approvals for these indications.

References

  1. [1]
    FDA approves selinexor for refractory or relapsed multiple myeloma
    Dec 18, 2020 · FDA granted selinexor accelerated approval in 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or ...
  2. [2]
    FDA approves selinexor for relapsed/refractory diffuse large B-cell ...
    Jun 22, 2020 · The recommended selinexor dosage for patients with DLBCL is 60 mg taken orally on days 1 and 3 of each week with antiemetic prophylaxis. View ...
  3. [3]
    Selinexor: A First-in-Class Nuclear Export Inhibitor for Management ...
    Selinexor is a first-in-class selective inhibitor of nuclear export which, through inhibition of exportin-1, causes accumulation of tumor suppressor proteins.
  4. [4]
    Selinexor - LiverTox - NCBI Bookshelf
    Apr 29, 2023 · Selinexor (sel” in nex' or) is a small molecule inhibitor of nuclear exportin-1 (XPO1) which blocks the transport of tumor suppressor proteins, ...
  5. [5]
    FDA Approval Summary: Selinexor for Relapsed or Refractory ...
    Selinexor showed modest, but clinically meaningful, efficacy in patients with relapsed or refractory DLBCL at the approved dosage, based on ORR and durability ...
  6. [6]
    Treatment of multiple myeloma with selinexor: a review - PMC
    Jan 5, 2024 · Selinexor is an oral XPO1 inhibitor that exerts anti-tumor activity through a novel mechanism. Here, we review the current clinical trials ...
  7. [7]
  8. [8]
    [PDF] XPOVIO (Selinexor) MULTI-DISCIPLINE REVIEW - accessdata.fda.gov
    Mar 13, 2019 · ... (ORR) observed in the STORM trial of 25.3% with a median duration of response (mDOR) of 3.8 months. Selinexor is associated with significant ...
  9. [9]
    [PDF] XPOVIO® (selinexor) tablets, for oral use - accessdata.fda.gov
    adult patients with multiple myeloma who have received at least one prior therapy (1.1). • In combination with dexamethasone for the treatment of adult patients.<|control11|><|separator|>
  10. [10]
    [PDF] Xpovio - accessdata.fda.gov
    5.7 Embryo-Fetal Toxicity​​ Selinexor administration to pregnant animals during organogenesis resulted in structural abnormalities and alterations to growth at ...
  11. [11]
    Selinexor-induced thrombocytopenia results from inhibition of ...
    Dashed lines mark periods of selinexor and/or TPO mimetic treatment. Dose interruption with TPO mimetics treatment help alleviate thrombocytopenia in patients.
  12. [12]
    Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound ...
    Oct 4, 2016 · Selinexor covalently binds to Cys-528 in the cargo-binding pocket of human XPO1 [54] leading to trapping of XPO1 cargo proteins in the nucleus.
  13. [13]
    Structural Basis of Targeting the Exportin CRM1 in Cancer - PMC
    Sep 18, 2015 · ... apoptosis of cancer cells. In contrast, in normal cells, these drugs, although they induced cell cycle arrest, do not lead to apoptosis.<|control11|><|separator|>
  14. [14]
    Clinical dosing regimen of selinexor maintains normal immune ... - NIH
    XPO1 facilitates transport of approximately 200 cargo proteins, including the tumor suppressor proteins p53, BRCA, IκB, p21, and FOXO (6). XPO1 also ...Missing: retention | Show results with:retention
  15. [15]
    Selective inhibitors of nuclear export (SINE)– a novel class of anti ...
    Oct 15, 2014 · SINE also caused G1/S phase cell cycle arrest, another effect synergized with concomitant BRAF inhibition in BRAF mutant cell lines. SINE also ...Missing: oncoprotein | Show results with:oncoprotein
  16. [16]
    The past, present, and future of CRM1/XPO1 inhibitors - PMC
    Feb 25, 2019 · Similar to their predecessors, these molecules form covalent bonds to a cysteine residue (Cys528) on CRM1 (21). However, they improve upon ...
  17. [17]
    XPO1 target occupancy measurements confirm the selinexor ...
    Nov 30, 2017 · XPO1 is overexpressed in tumor cells and high levels are correlated with poor prognosis. Selective Inhibitor of Nuclear Export (SINE) compounds ...
  18. [18]
    Nuclear Export in Non-Hodgkin Lymphoma and Implications for ...
    Jan 5, 2023 · It was therefore of interest to investigate whether selinexor could enhance the efficacy of bendamustine via nuclear retention of p53.
  19. [19]
    XPO1 target occupancy measurements confirm the selinexor ... - NIH
    XPO1 is overexpressed in tumor cells and high levels are correlated with poor prognosis. Selective Inhibitor of Nuclear Export (SINE) compounds block nuclear ...
  20. [20]
    [PDF] This label may not be the latest approved by FDA. For current ...
    The most common adverse reactions (≥20% with a difference between arms of >5% compared to Vd) were. 12. Reference ID: 4719344. This label may not be the latest ...
  21. [21]
    Selinexor | C17H11F6N7O | CID 71481097 - PubChem - NIH
    7.6 Biological Half-Life. Selinexor has a mean half-life of elimination of 6-8 hours. DrugBank. 7.7 Mechanism of Action. Selinexor binds to and inhibits ...Missing: bioavailability | Show results with:bioavailability
  22. [22]
    Selinexor: Uses, Interactions, Mechanism of Action | DrugBank Online
    The FDA approved Selinexor in June 2019. ... With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & ...Identification · Pharmacology · Interactions · References
  23. [23]
    Selinexor (KPT-330) | CRM1 inhibitor | Mechanism | Concentration
    Chemical Information ; Molecular Weight, 443.31, Formula ; CAS No. 1393477-72-9, SDF ; Synonyms, ATG-010 ; Smiles, C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C ...Missing: properties: IUPAC logP pKa appearance plasma binding Michael
  24. [24]
    [PDF] XPOVIO (Selinexor) Chemistry Review - accessdata.fda.gov
    Aug 24, 2018 · Selinexor is an orally bioavailable, potent, selective, first-in-class, small molecule XPO1 inhibitor. The drug product,. Selinexor Tablets ...
  25. [25]
    Abstract 2442: XPO1 is selinexor prime target: validation by mutating ...
    The binding of selinexor to XPO1 involves a slowly reversible Michael addition type interaction of its acrylate moiety with cysteine 528 residue of XPO1.
  26. [26]
    A Phase II Study of the Efficacy and Safety of Oral Selinexor in ...
    Importantly, selinexor is a covalent inhibitor, forming a reversible covalent bond (t½ ∼24 hours) with Cys528 in XPO1, for a relatively long, effective ...
  27. [27]
    KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear ...
    Jun 24, 2016 · SINE compounds covalently bind to cysteine528 in the cargo-binding groove of XPO1 to block the interaction of XPO1 with its cargo and hence ...
  28. [28]
    Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT ...
    Jul 25, 2012 · KPT-330 is the first oral SINE CRM1 antagonist to enter human studies. SINEs specifically and irreversibly inhibit the nuclear export protein ...
  29. [29]
    KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has ...
    Feb 4, 2013 · KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-ALL and AML.Missing: genotoxicity cardiotoxicity
  30. [30]
    Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound ...
    Nov 29, 2016 · Selinexor, a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound, binds covalently to XPO1 and blocks its function.Results · Iκb-α Silencing Decreases... · Selinexor Inhibits Nf-κb...Missing: original | Show results with:original
  31. [31]
    Investor Relations | Karyopharm Therapeutics - Press Releases
    Jan 8, 2015 · "Orphan Drug Designation by the FDA for multiple myeloma is another significant milestone in the selinexor development program," commented Dr.Missing: 2012 | Show results with:2012
  32. [32]
    FDA grants accelerated approval to selinexor for multiple myeloma
    Jul 3, 2019 · The recommended selinexor dose is 80 mg in combination with dexamethasone taken orally on days 1 and 3 of each week. View full prescribing ...
  33. [33]
    Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple ...
    Aug 21, 2019 · Selinexor–dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.Missing: bioavailability | Show results with:bioavailability
  34. [34]
    [PDF] Assessment report - Nexpovio - European Medicines Agency
    Jan 28, 2021 · Overexpression of XPO1 has been suggested to occur in a variety of malignancies including multiple myeloma where it has been linked to ...
  35. [35]
    Nexpovio | European Medicines Agency (EMA)
    ### Approved Therapeutic Indications for Nexpovio (Selinexor)
  36. [36]
    Xpovio | Therapeutic Goods Administration (TGA)
    Mar 24, 2022 · TGA decision: Xpovio (selinexor) is approved to treat multiple myeloma ... TGA, will be implemented in Australia. An obligatory component ...
  37. [37]
    KEGG DRUG: Selinexor
    New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11222 Drug metabolizing enzymes and transporters ...
  38. [38]
    Summary Basis of Decision for Xpovio
    Jul 17, 2023 · Selinexor is eliminated by the hepatobiliary route in feces with minimal excretion in urine. The results of the non-clinical studies as well ...
  39. [39]
    [PDF] XPOVIO (Selinexor) Risk Assessment and Risk Mitigation Review(s)
    Jul 6, 2019 · The FDA clinical reviewer recommends approval of selinexor on the basis of the efficacy and safety information currently available. The ...
  40. [40]
    XPOVIO (selinexor) Available for Order at Biologics by McKesson
    XPOVIO is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma ...Missing: manufacturer | Show results with:manufacturer
  41. [41]
    FDA Approves Xpovio™ to Treat Multiple Myeloma, Despite ...
    The drug will carry a list price of $22,000 per month. The FDA advises healthcare professionals monitor patients for low blood count, platelets, ...
  42. [42]
    10-K - SEC.gov
    The U.S. patents covering the polymorph used in selinexor's commercial drug substance will expire in August 2035. Any other patents that may issue in the U.S. ...
  43. [43]
  44. [44]
    Investor Relations | Karyopharm Therapeutics - Press Releases
    Nov 7, 2018 · Selinexor has been granted Orphan Drug Designation in multiple myeloma and Fast Track designation for the patient population evaluated in the ...
  45. [45]
    Search Orphan Drug Designations and Approvals - FDA
    selinexor ... in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...Missing: KPT- 330 2012
  46. [46]
    Karyopharm Announces Preliminary Unaudited 2024 Revenue and ...
    Jan 13, 2025 · Expanded global patient access for selinexor in 2024 with favorable reimbursement decisions in the United Kingdom, France, Italy, China and ...
  47. [47]
    Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center ...
    May 12, 2025 · The company highlighted that XPOVIO/selinexor has been approved in over 45 countries globally, providing a strong foundation for future ...
  48. [48]
    Patient Support Program | XPOVIO® (selinexor)
    Patient Assistance Program for uninsured and underinsured patients, can provide XPOVIO at no cost · Copay assistance for eligible, commercial insured patients ...
  49. [49]
    10-K - SEC.gov
    Any patents that may issue in the U.S. as part of our selinexor patent portfolio will expire no earlier than 2032, not including any terminal disclaimer, patent ...
  50. [50]
    Selinexor, bortezomib and dexamethasone shows PFS benefit for ...
    Jun 19, 2023 · The BOSTON trial confirms the PFS benefit of selinexor, bortezomib, and dexamethasone over bortezomib, and dexamethasone in patients without prior PI or ...
  51. [51]
    Association of Selinexor Dose Reductions With Clinical Outcomes in ...
    Duration-adjusted AE rates that were lower after selinexor dose reduction included thrombocytopenia (62.5% before vs. 47.6% after), nausea (31.6% vs. 7.3%), ...
  52. [52]
    Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in ...
    May 31, 2023 · Prior studies have reported an overall response rate (ORR) of 28% and a median progression free survival (mPFS) of 3.7 mos to pomalidomide + low ...Missing: reduced | Show results with:reduced
  53. [53]
  54. [54]
    Lower dose and weekly schedules of selinexor in multiple myeloma
    Sep 21, 2025 · The Phase 2b Selinexor in the Treatment of Relapsed Myeloma (STORM) study (NCT02336815) evaluating the doublet combination of selinexor 80 mg ...
  55. [55]
  56. [56]
    From Triple- to Penta-Exposed Multiple Myeloma: A Real-World ...
    Aug 4, 2024 · This study examined treatment patterns, time to discontinuation (TTD), time to next treatment (TTNT), overall survival (OS), HRU, and HCC (2021 ...
  57. [57]
    Study Details | NCT02227251 | Selinexor (KPT-330) in Patients With ...
    A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
  58. [58]
    Phase IB Study of Oral Selinexor in Combination with Rituximab and ...
    We conducted a study investigating the combination of selinexor with rituximab and platinum-based chemotherapy in B-cell lymphoma. Patients and methods: We ...
  59. [59]
    Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
    This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve ...Missing: II 001
  60. [60]
    Karyopharm Reports First Quarter 2025 Financial Results and ...
    May 12, 2025 · Karyopharm reports first quarter 2025 financial results and announces new data in myelofibrosis that further suggests selinexor may lead to meaningful spleen ...
  61. [61]
    Real-world experience with selinexor-containing chemotherapy-free ...
    Aug 3, 2023 · This study aimed to evaluate the efficacy and safety of chemotherapy-free or low-dose chemotherapy regimens with selinexor for R/R AML and MS patients.
  62. [62]
    NCT03955783 | Venetoclax and Selinexor in Treating Patients with ...
    This phase Ib trial studies the toxicity and dosing of venetoclax in combination with selinexor, and how well the combination works in treatment of patients ...Missing: 2023 | Show results with:2023
  63. [63]
    Selinexor Combined With Ruxolitinib Shows Promising Results in ...
    Dec 18, 2024 · Combined with the exporter-1 inhibitor, selinexor, ruxolitinib reduces spleen volume and reduces symptoms for participants with myelofibrosis (MF)Missing: XPORT- | Show results with:XPORT-
  64. [64]
    Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis
    Eligible patients will be randomized 2:1 to receive treatment with either 60 mg oral once weekly selinexor plus ruxolitinib or placebo plus ruxolitinib ...
  65. [65]
    Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma
    Apr 8, 2022 · We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.
  66. [66]
    Study Details | NCT02606461 | Selinexor in Advanced Liposarcoma
    Phase 2 Double Blind: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined ...Missing: II | Show results with:II
  67. [67]
    Phase II Trial of Selinexor for Metastatic Triple-Negative Breast Cancer
    Selinexor was fairly well tolerated in patients with advanced TNBC but did not result in objective responses. However, clinical benefit rate was 30%.Missing: pembrolizumab | Show results with:pembrolizumab
  68. [68]
    Phase Ib study of selinexor and eribulin combination in advanced ...
    Jun 2, 2022 · Conclusions: Selinexor with eribulin is safe with manageable toxicity profile and modest overall clinical efficacy. Durable responses and ...
  69. [69]
    A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear ...
    This phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration‐resistant prostate cancer (mCRPC) refractory to ...Missing: 2025 | Show results with:2025
  70. [70]
    Preclinical antitumor efficacy of selective exportin 1 inhibitors in ...
    Nov 2, 2014 · Based on these preclinical data and excellent brain penetration, we have initiated clinical trials of Selinexor in patients with relapsed GBM.
  71. [71]
    [PDF] Treatment of Severe COVID-19 with Low-Dose Selinexor
    Placebo-Controlled Phase 2 Clinical Trial. George Geils Jr., Zainab Shahid, Don Stevens, Nathan C. Bahr, Jacek Skarbinski,. Vaishali Sanchorawala, Marcelo ...
  72. [72]
    NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in ...
    The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, ...